Vir Biotechnology (VIR) Gross Margin (2020 - 2026)
Vir Biotechnology (VIR) posted Gross Margin of 99.09% for Q2 2025, down 0.91% sequentially from 100.0% in Q1 2025, and up 78.0% YoY from 55.67% in Q2 2024.
Vir Biotechnology (VIR) Gross Margin (2020 - 2026) Analysis & Trends
Vir Biotechnology has reported Gross Margin for 6 years, with the latest figure at 99.09% in Q2 2025.
- Quarterly Gross Margin rose 78.0% year-over-year to 99.09% in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 96.08% (down 264.0% YoY) and the FY2025 annual result came in at 99.96%, up 110.0% from the prior year.
- Gross Margin eased to 99.09% in Q2 2025 per VIR's latest filing, from 100.0% in the prior quarter.
- Over five years, Gross Margin peaked at 100.0% in Q1 2021 and troughed at 31.28% in Q2 2022.
- A 5-year average of 92.81% and a median of 97.44% in 2024 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2022 and 2023: Gross Margin tumbled 6804 bps in 2022, then soared 6814 bps in 2023.
- Over 5 years, Gross Margin stood at 93.0% in 2021, then declined by 6 bps to 87.86% in 2022, then climbed by 8 bps to 95.25% in 2023, then slipped by 1 bps to 94.47% in 2024, then climbed by 5 bps to 99.09% in 2025.
- According to Business Quant data, Gross Margin over the past three periods registered 99.09%, 100.0%, and 94.47% for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 100.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100.00% |
| Jun 30, 2025 | 99.09% |
| Mar 31, 2025 | 100.00% |
| Dec 31, 2024 | 94.47% |
| Sep 30, 2024 | 97.90% |
| Jun 30, 2024 | 98.31% |
| Mar 31, 2024 | 99.89% |
| Dec 31, 2023 | 95.25% |
| Sep 30, 2023 | 98.56% |
| Jun 30, 2023 | 99.42% |
| Mar 31, 2023 | 96.97% |
| Dec 31, 2022 | 87.86% |
| Sep 30, 2022 | 94.06% |
| Jun 30, 2022 | 31.28% |
| Mar 31, 2022 | 92.69% |
| Dec 31, 2021 | 93.00% |
| Sep 30, 2021 | 92.44% |
| Jun 30, 2021 | 99.32% |
| Mar 31, 2021 | 100.00% |
| Dec 31, 2020 | 100.00% |